問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-Department of Medical Imaging

Division of Radiology

Division of Radiation Therapy

Digestive System Department

Division of General Internal Medicine

Division of Urology

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Radiology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Radiology

更新時間：2023-09-19

梁博欽-, -
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

梁博欽

List

59Cases

2020-01-01 - 2027-07-31

Phase III

Active
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

  • Condition/Disease

    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

  • Test Drug

    Keytruda® Xtandi®

Participate Sites
5Sites

Recruiting5Sites

2020-03-01 - 2028-12-31

Phase III

Active
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

  • Condition/Disease

    Incurable/Non-metastatic Hepatocellular Carcinoma

  • Test Drug

    Pembrolizumab (Keytruda)； Lenvatinib (Lenvima)

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

2008-02-01 - 2012-02-28

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2016-01-01 - 2023-08-01

Phase I

Completed
PHASE I DOSE-ESCALATING STUDY OF INTRAARTERIAL ADMINISTRATION OF TIRAPAZAMINE FOLLOWED BY TRANSARTERIAL EMBOLIZATION (TAE) FOR TREATMENT OF HEPATOCELLULAR CARCINOMA

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    Tirapazamine

Participate Sites
4Sites

Not yet recruiting4Sites

2014-05-01 - 2016-01-01

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-12-01 - 2026-12-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2016-10-01 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-06-01 - 2026-12-31

Others

Active
CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    注射液

Participate Sites
4Sites

Recruiting4Sites

2014-04-01 - 2017-01-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2022-05-02 - 2028-12-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB